Form 10-K for the fiscal year ended December 31, 2024
You disclose on page 106 that do not allocate all of your costs by vaccine candidates, as your research and development expenses include internal costs, such as payroll and other personnel expenses, which are not tracked by vaccine candidate.Rest of the question
Please provide revised disclosure to be included in future filings to address the following: • Clarify which expenses you do allocate by project and clarify if you track any expenses by candidate. To the extent you do track any research and development expenses by program, provide a breakdown of the expenses tracked by project. If you do not track external expenses by program, break out external research and development costs by clinical and preclinical. If you cannot disaggregate these • 1. amounts, please disclose that fact and explain why not. • For all other research and development expenses. provide us with other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e. by nature or type of expense) which should reconcile to total research and development expense on the Statements of Operations. We note that you included a break out of research and development expenses by type in the 10-K for the year ended December 31, 2023.
The Company acknowledges the Staff’s comment and respectfully advises the Staff that we track our research and development (“R&D”) expenses by major types of expense, and we do not have a systematic approach to allocate R&D expenses by candidate, program and/or project. Our R&D expenses include:Read in the reply
1)External costs:
a)Product manufacturing costs: This includes costs related to acquiring, developing, and manufacturing supplies for clinical trials and to prepare for potential future commercial launches, including fees paid to contract manufacturing organizations.
b)Clinical costs: This includesRest of the answer
costs and expenses related to agreements with contract research organizations, investigator sites, and consultants to conduct clinical trials.
c)R&D consumables costs, laboratory supplies and equipment costs.
d)Facility and allocated costs.
e)Other expenses, which primarily include professional and consulting services costs.
Also in this review: closing letter, 2025-05-14